{"task_id": "a2237b1fad37a2a7", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 267/464)", "text": "ce both, particularly trough level\n256\nAntibiotics\n\n--- Page 278 ---\nPENICILLIN ALLERGY\nHISTORY\ncharacterize reaction (age when reaction\noccurred, timing of reaction after penicillin adminis\ntration, type of reaction, route of administration, rea\nson for penicillin, any other medications at the time,\nresolution), any similar antibiotics since\nCROSS REACTIVITY\nincidence of cross reactivity\nto cephalosporins when patient has penicillin allergy\nby history is <2%. Carbapenems and first/second\ngeneration cephalosporins have higher cross reactiv\nity in the penicillin allergic than third generation\ncephalosporins and aztreonam. It is often safe to\nuse these medications, with the first dose monitored.\nIf safety unclear, skin testing provides reassurance.\nFor patients with a history of penicillin allergy, those\nwith positive and negative skin test have 5.6% and\n1.7% chance of developing cross reactivity with\ncephalosporin, respectively\nNEJM 2006 354:6\nRATIONAL CLINICAL EXAMINATION SERIES: IS\nTHIS PATIENT ALLERGIC TO PENICILLIN?\nHISTORY\nhistory of penicillin allergy (LR+ 1.9,\nLR\n0.5)\nTYPES OF ALLERGIC REACTIONS\nwACIDw\nAntibody mediated\n(IgE),\nCytotoxic\n(antibody dependent), Immune complex mediated,\nDelayed hypersensitivity reaction\nPENICILLIN ALLERGY (CONT\u2019D)\n\u0002\nTYPE\nI\nimmediate\n<1\nh,\nIgE\nantibodies\nmediated, anaphylaxis, hypotension, laryngeal\nedema, wheezing, angioedema, urticaria\n\u0002\nTYPE II\n>72 h, IgG and complement mediated,\nincreased clearance of RBC and platelets by lym\nphoreticular system\n\u0002\nTYPE III\n>72 h, IgG and IgM immune com\nplexes mediated, serum sickness, tissue injury\n\u0002\nTYPE IV\n>72 h, contact dermatitis\n\u0002\nOTHERS\n>72 h, maculopapular or morbilliform\nrashes\nAPPROACH\n\u2018\u2018only 10 20% of patients reporting\na history of penicillin allergy are truly allergic\nwhen assessed by skin testing. Taking a detailed\nhistory of a patient\u2019s reaction to penicillin may\nallow clinicians to exclude true penicillin allergy,\nallowing these patients to receive penicillin.\nPatients with a concerning history of type I peni\ncillin allergy who have a compelling need for a\ndrug containing penicillin should undergo skin\ntesting. Virtually all patients with a negative skin\ntest result can take penicillin without serious\nsequelae\u2019\u2019\nJAMA 2001 285:19\nApproach to Empiric Antibiotics\nGENERAL APPROACH\nCHOICE OF EMPIRIC ANTIBIOTIC\nbased on the\nmost likely and deadly organisms for each type of\ninfection. Thus, a good understanding of the patho\nphysiology of each infection and the local resistance\npattern of various organisms is essential\nCULTURE AND SUSCEPTIBILITY\nshould always be\nperformed to facilitate targeted antibiotic treatment\nexcept for mild infections. However, the specific\norganism may not be identified even if multiple\ncultures are taken. In this case, the clinician must\nrely on clinical judgment and continue treatment\nwith empiric antibiotic(s)\nSPECIFIC INFECTIONS AND EMPIRIC ANTIBIOTIC\nCHOICES\nSEPSIS\ndepending on the suspected source. For\npulmonary\nsource,\nrespiratory\nfluoroquinolone\nplus ceftriaxone \u0006 vancomycin if community set\nting, anti pseudomonal plus ciprofloxacin if hospi\ntal setting. For urinary source, ceftriaxone or\nSPECIFIC INFECTIONS AND EMPIRIC ANTIBIOTIC\nCHOICES (CONT\u2019D)\ncarbapenem or fluoroquinolone or aminoglycoside.\nFor intra abdominal source, pipericillin tazobactam\nplus aminoglycoside. Duration of treatment is at\nleast 10 14 days with rationalization of antibiotics\nwhen susceptibility results available. See p. 97 for\ndetails\nMENINGITIS (S. pneumoniae, N. meningitidis, Listeria,\nHSV)\nceftriaxone/cefotaxime \u0006 ampicillin \u0006 vanco\nmycin. Add acyclovir if CSF suggests viral picture.\nDuration of treatment is 7 21 days. See p. 241 for\ndetails\nCOMMUNITY ACQUIRED PNEUMONIA (S. pneumo\nniae, Klebsiella, Mycoplasma)\nmacrolides \u0006 cefotax\nime or respiratory fluoroquinolones. Duration of\ntreatment is usually 7 days. See p. 6 for details\nASPIRATION\nPNEUMONIA\n(anaerobes,\nStaph,\nGNB)\ncefotaxime \u0006 clindamycin or metronidazole.\nDuration of treatment is usually at least 7 days. See p.\n6 for details\nApproach to Empiric Antibiotics\n257", "text_length": 4079, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 267/464)", "type": "chunk", "chunk_index": 266, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.614137", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.614881", "status": "complete", "chunks_added": 3}